Trastuzumab – USA

Trastuzumab – USA

Decision on IPR: Nov 20, 2018

AIA Review
Filing Date
Institution Date
Petitioner
US Patent
Respondent
Status
IPR2017-02019
08/29/2017
03/12/2018
Pfizer, Inc.
6,339,142
Genentech, Inc.
Terminated
IPR2017-02020
08/29/2017
03/12/2018
Pfizer, Inc.
9,249,218
Genentech, Inc.
Terminated
On US’142 & US’218 patents, Pfizer previously filed IPRs (IPR2018-00330 & IPR2018-00331) on 12/18/2017 which were denied by PTAB.

US 6,339,142 (Genentech, Inc.; Exp: May 03, 2019):

1. A composition comprising a mixture of anti-HER2 antibody and one or more acidic variants thereof, wherein the amount of the acidic variant(s) is less than about 25%.
US 9,249,218 (Genentech, Inc.; Exp: May 03, 2019*TD):

1. A therapeutic composition comprising a mixture of anti-HER2 antibody and one or more acidic variants thereof, wherein the amount of the acidic variant(s) is less than about 25%, and wherein the acidic variant(s) are predominantly deamidated variants wherein one or more asparagine residues of the anti-HER2 antibody have been deamidated, and wherein the anti-HER2 antibody is humMAb4D5-8, and wherein the deamidated variants have Asn30 in CDR1 of either or both V.sub.L regions of humMAb4D5-8 converted to aspartate, and a pharmaceutically acceptable carrier.

Leave a Reply

Leave a Reply

Your email address will not be published.

Disclaimer
All content provided on this blog is for informational purposes only. By using the blog, you agree that the information on this blog does not constitute legal or other professional advice on author's or on his company's behalf.

Copyrights 2022 Pharma IP Circle. All Rights Reserved